Ovid Therapeutics to Participate in Upcoming Investor Conferences Feb 25, 2026 07:00AM
Ovid Therapeutics raises up to $175 million in private placement Oct 3, 2025 07:05AM
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds Oct 3, 2025 07:05AM
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Mar 11, 2025 08:00AM
Ovid Therapeutics (OVID) Appoints Stelios Papadopoulos to its Board Mar 3, 2025 08:03AM


Mar 3, 2025 08:00AM Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
Feb 27, 2025 08:00AM Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Jul 2, 2024 10:20AM TD Cowen Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
Jun 18, 2024 09:55AM TD Cowen Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
Feb 28, 2024 08:00AM Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Feb 28, 2023 08:00AM Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
Feb 28, 2023 08:00AM Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
Mar 4, 2022 08:00AM Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
Aug 25, 2020 07:52AM Ovid Therapeutics (OVID) Announces Pricing of $50 Million Offering of Common Stock at $8/sh
Aug 25, 2020 07:50AM Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
Feb 25, 2020 08:00AM Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
Oct 4, 2019 08:34AM Ovid Therapeutics (OVID) Prices 9M Share Common Offering at $2.50/Sh; Announces Pricing on Concurrent 4,000 Series A Convertible Preferred Share Offering
Oct 4, 2019 08:30AM Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
Oct 4, 2019 08:30AM Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
Oct 3, 2019 04:01PM Ovid Therapeutics (OVID) Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Oct 3, 2019 04:01PM Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Oct 3, 2019 04:01PM Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Mar 4, 2019 08:00AM Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
Mar 4, 2019 08:00AM Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
Feb 20, 2019 09:12AM UPDATE: Ovid Therapeutics (OVID) Prices 12.5M Share Common Offering at $2/Sh; Announces Pricing of 2500 Preferred Share Offering
Feb 20, 2019 09:08AM Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Feb 20, 2019 09:08AM Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Feb 19, 2019 04:05PM Ovid Therapeutics (OVID) Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Feb 19, 2019 04:01PM Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Feb 19, 2019 04:01PM Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Sep 4, 2018 04:05PM Dr. Yaron Werber, Chief Business and Financial Officer, to Return to Wall Street
Sep 4, 2018 04:05PM Dr. Yaron Werber, Chief Business and Financial Officer, to Return to Wall Street
Mar 5, 2018 04:05PM Ovid Therapeutics to Present at Two Upcoming Investor Conferences
Mar 5, 2018 04:05PM Ovid Therapeutics to Present at Two Upcoming Investor Conferences
May 30, 2017 05:49AM Cowen Starts Ovid Therapeutics Inc (OVID) at Outperform
May 5, 2017 10:43AM Ovid Therapeutics (OVID) IPO Opens 7% Lower
May 4, 2017 06:20PM Ovid Therapeutics Announces Pricing of Initial Public Offering